|
1
|
Belghiti J and Kianmanesh R: Surgical
treatment of hepatocellular carcinoma. HPB Oxf. 7:42–49. 2005.
View Article : Google Scholar
|
|
2
|
Marin JJ, Castaño B, Martinez-Becerra P,
Rosales R and Monte MJ: Chemotherapy in the treatment of primary
liver tumours. Cancer Ther. 6:711–728. 2008.
|
|
3
|
Wang Y and Shen Y: Unresectable
hepatocellular carcinoma treated with transarterial
chemoembolization: Clinical data from a single teaching hospital.
Int J Clin Exp Med. 6:367–371. 2013.PubMed/NCBI
|
|
4
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Z, Lu W, Garcia-Prieto C and Huang P:
The Warburg effect and its cancer therapeutic implications. J
Bioenerg Biomembr. 39:267–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsu CC, Lee HC and Wei YH: Mitochondrial
DNA alterations and mitochondrial dysfunction in the progression of
hepatocellular carcinoma. World J Gastroenterol. 19:8880–8886.
2013. View Article : Google Scholar :
|
|
9
|
Lee HC and Wei YH: Mitochondrial DNA
instability and metabolic shift in human cancers. Int J Mol Sci.
10:674–701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tennant DA, Durán RV and Gottlieb E:
Targeting metabolic transformation for cancer therapy. Nat Rev
Cancer. 10:267–277. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma XM and Blenis J: Molecular mechanisms
of mTOR-mediated translational control. Nat Rev Mol Cell Biol.
10:307–318. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimobayashi M and Hall MN: Making new
contacts: The mTOR network in metabolism and signalling crosstalk.
Nat Rev Mol Cell Biol. 15:155–162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fernandez P, Carretero J, Medina PP,
Jimenez AI, Rodriguez-Perales S, Paz MF, Cigudosa JC, Esteller M,
Lombardia L, Morente M, et al: Distinctive gene expression of human
lung adenocarcinomas carrying LKB1 mutations. Oncogene.
23:5084–5091. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang YH, Chen ZK, Huang KT, Li P, He B,
Guo X, Zhong JQ, Zhang QY, Shi HQ, Song QT, et al: Decreased
expression of LKB1 correlates with poor prognosis in hepatocellular
carcinoma patients undergoing hepatectomy. Asian Pac J Cancer Prev.
14:1985–1988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sahin F, Maitra A, Argani P, Sato N,
Maehara N, Montgomery E, Goggins M, Hruban RH and Su GH: Loss of
Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod
Pathol. 16:686–691. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shen Z, Wen XF, Lan F, Shen ZZ and Shao
ZM: The tumor suppressor gene LKB1 is associated with prognosis in
human breast carcinoma. Clin Cancer Res. 8:2085–2090.
2002.PubMed/NCBI
|
|
23
|
Hezel AF and Bardeesy N: LKB1; linking
cell structure and tumor suppression. Oncogene. 27:6908–6919. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen HP, Shieh JJ, Chang CC, Chen TT, Lin
JT, Wu MS, Lin JH and Wu CY: Metformin decreases hepatocellular
carcinoma risk in a dose-dependent manner: Population-based and in
vitro studies. Gut. 62:606–615. 2013. View Article : Google Scholar
|
|
26
|
Hassan MM, Curley SA, Li D, Kaseb A,
Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese
JL, et al: Association of diabetes duration and diabetes treatment
with the risk of hepatocellular carcinoma. Cancer. 116:1938–1946.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Petrushev B, Tomuleasa C, Soritau O, Aldea
M, Pop T, Susman S, Kacso G, Berindan I, Irimie A and Cristea V:
Metformin plus PIAF combination chemotherapy for hepatocellular
carcinoma. Exp Oncol. 34:17–24. 2012.PubMed/NCBI
|
|
29
|
Pollak M: Potential applications for
biguanides in oncology. J Clin Invest. 123:3693–3700. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalender A, Selvaraj A, Kim SY, Gulati P,
Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et
al: Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu CC, Wang CH, Wu LC, Hsia CY, Chi CW,
Yin PH, Chang CJ, Sung MT, Wei YH, Lu SH, et al: Mitochondrial
dysfunction represses HIF-1α protein synthesis through AMPK
activation in human hepatoma HepG2 cells. Biochim Biophys Acta.
1830:4743–4751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stephenne X, Foretz M, Taleux N, van der
Zon GC, Sokal E, Hue L, Viollet B and Guigas B: Metformin activates
AMP-activated protein kinase in primary human hepatocytes by
decreasing cellular energy status. Diabetologia. 54:3101–3110.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bodmer M, Meier C, Krähenbühl S, Jick SS
and Meier CR: Long-term metformin use is associated with decreased
risk of breast cancer. Diabetes Care. 33:1304–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chlebowski RT, McTiernan A,
Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani
VG, Vitolins M, Wallace R, et al: Diabetes, metformin, and breast
cancer in postmenopausal women. J Clin Oncol. 30:2844–2852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bodmer M, Becker C, Meier C, Jick SS and
Meier CR: Use of antidiabetic agents and the risk of pancreatic
cancer: A case-control analysis. Am J Gastroenterol. 107:620–626.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li D, Yeung SC, Hassan MM, Konopleva M and
Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic
cancer. Gastroenterology. 137:482–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
LeBleu VS, O'Connell JT, Gonzalez Herrera
KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A,
Domingos Chinen LT, Rocha RM, et al: PGC-1α mediates mitochondrial
biogenesis and oxidative phosphorylation in cancer cells to promote
metastasis. Nat Cell Biol. 16:992–1003. 1001–1015. 2014. View Article : Google Scholar
|
|
39
|
Tan AS, Baty JW, Dong LF, Bezawork-Geleta
A, Endaya B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B,
et al: Mitochondrial genome acquisition restores respiratory
function and tumorigenic potential of cancer cells without
mitochondrial DNA. Cell Metab. 21:81–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: Meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vander Heiden MG, Christofk HR, Schuman E,
Subtelny AO, Sharfi H, Harlow EE, Xian J and Cantley LC:
Identification of small molecule inhibitors of pyruvate kinase M2.
Biochem Pharmacol. 79:1118–1124. 2010. View Article : Google Scholar :
|
|
43
|
Le A, Cooper CR, Gouw AM, Dinavahi R,
Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang
CV: Inhibition of lactate dehydrogenase A induces oxidative stress
and inhibits tumor progression. Proc Natl Acad Sci USA.
107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wong N, De Melo J and Tang D: PKM2, a
central point of regulation in cancer metabolism. Int J Cell Biol.
2013:2425132013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
